3.8 Article

Construction and validation of a list of common Middle Eastern surnames for epidemiological research

Journal

CANCER DETECTION AND PREVENTION
Volume 31, Issue 5, Pages 424-429

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cdp.2007.10.006

Keywords

Middle East; name list; epidemiology; ethnic identification; ethnic studies

Categories

Funding

  1. NCI NIH HHS [N01-PC-35136, R03 CA103457-01, N01-PC-35139, R03 CA103457-02, R03 CA103457, N01-PC-54404] Funding Source: Medline
  2. NCCDPHP CDC HHS [1U58DP00807-01] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [R03CA103457] Funding Source: NIH RePORTER
  4. NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [U58DP000807] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Purpose: Middle Eastern (ME) population is rapidly growing in the US but cannot be easily identified in cancer registry or other databases for epidemiological research. The purpose of this study was to develop a list of common Middle Eastern surnames and validate it by linking with a cancer registry incidence files. Methods: Surnames and place of birth in the Middle East were obtained from various sources. After exclusion of the non-specific entries, the final combined list included 49,6 10 surnames and was matched with the California Cancer Registry incidence file for 1988-2003. Results: Overall, 1.4% of all registered cases were positively identified as ME that is similar to the proportion of ME population in California. Two third of the identified cases had known place of birth in the Middle East and of those, 70% were non-Arabs. The sensitivity of the list in detecting ME birth in men and women are 9 1% and 86%, respectively. The positive predictive values for men and women are 72% and 65%. The specificity and negative predictive values are universally over 99%. Conclusion: The high accuracy reported for this Middle Eastern surname list (MESL) makes it a valuable tool for epidemiological studies of this ethnic population. (c) 2007 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available